Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for Hospitalized Adult Patients With COVID-19
view all Clinical Trials
Overview
The primary objectives are:
Phase 1
- To evaluate the safety and tolerability of REGN10933+REGN10987 compared to placebo
- To evaluate the virologic efficacy of REGN10933+REGN10987 compared to placebo in reducing viral shedding of SARS-CoV-2 Phase 2
- To evaluate the virologic efficacy of REGN10933+REGN10987 compared to placebo in reducing viral shedding of SARS-CoV-2
- To evaluate the clinical efficacy of REGN10933+REGN10987 compared to placebo in improving clinical status Phase 3
- To evaluate and confirm the clinical efficacy of REGN10933+REGN10987 compared to placebo in improving clinical status
Contact
For more information about this trial or to inquire about eligibility, email breathe@tuhs.temple.edu or call 215-707-1359.